Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BRCA genes
MedTech
AstraZeneca re-ups ties with Chinese cancer test maker AmoyDx
AstraZeneca is once again tapping the Shanghai-based developer Amoy Diagnostics for new companion tests to be paired up with its cancer medicines.
Conor Hale
Apr 18, 2022 10:42am
New discovery could open up PARP inhibitors to more patients
Jul 24, 2019 11:00am
AZ, Merck, Myriad to test BRACAnalysis in prostate cancer
Apr 4, 2019 11:55am
Myriad, Pfizer sign BRCA IVD commercial deal before FDA verdict
Oct 10, 2018 11:20am
Could even more cancer patients benefit from PARP inhibitors?
Jul 16, 2018 12:37pm
